Comparative Pharmacology
Head-to-head clinical analysis: MOUNJARO KWIKPEN versus VICTOZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOUNJARO KWIKPEN versus VICTOZA.
MOUNJARO KWIKPEN vs VICTOZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist; enhances glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying, and promotes satiety.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Subcutaneous injection once weekly. Initial dose: 2.5 mg for 4 weeks; then increase to 5 mg for at least 4 weeks; further increments of 2.5 mg every 4 weeks as tolerated, up to a maximum of 15 mg once weekly.
Subcutaneous injection: 0.6 mg once daily for 1 week, then increase to 1.2 mg once daily. May further increase to 1.8 mg once daily if needed for glycemic control.
None Documented
None Documented
Terminal elimination half-life is approximately 5 days (range 4-6 days), supporting once-weekly dosing. Steady state is achieved after 4 weeks of once-weekly administration.
After subcutaneous administration, the terminal elimination half-life is approximately 13 hours, supporting once-daily dosing.
Approximately 70% of the administered dose is eliminated via the kidneys (urine) and 30% via the feces (biliary/fecal route).
Liraglutide is eliminated via degradation by general proteolysis and not by specific enzymes; the intact drug is not excreted in urine or feces. Degraded metabolites are excreted via urine and feces.
Category C
Category C
Dual GIP/GLP-1 Receptor Agonist
GLP-1 Receptor Agonist